Skip to main content
Figure 2 | BMC Biotechnology

Figure 2

From: Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization

Figure 2

Antigen binding identification of FD006 to bind VEGF. (A) The binding activity of FD006 by ELISA; (B) Affinity detection of FD006 by binding kinetics assays; (C) The inhibitory effects of FD006 on VEGF-induced human umbilical vein endothelial cell (HUVEC) proliferation. The proliferation percentage was calculated using the formula ODsample/ODuntreated × 100 %. Data points represent the mean 6 SD of values acquired in duplicate.

Back to article page
\